
	Where results make sense

Topic: Betaseron

In the News (Sun 27 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	National MS Society \| Betaseron (Interferon beta-1b)
		Betaseron is a medication manufactured by a biotechnological process from one of the naturally occurring interferons (a type of protein).
		Betaseron is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations.
		Because of the potential of Betaseron to affect the functioning of the liver and thyroid gland, and to alter the levels of white blood cells, red blood cells, and platelets in a person's system, blood tests are recommended at regular intervals.
	www.nationalmssociety.org /Meds-InterferonBeta1b.asp (790 words)

	Betaseron/Betaferon - multiple sclerosis encyclopaedia
		Betaseron, known as Betaferon in Europe, is manufactured by Schering and its US associate Berlex.
		While not a cure, Betaseron has been shown in clinical trials to reduce the average relapse rate in people with the relapsing-remitting multiple sclerosis form of the disease.
		Betaseron is a form of beta interferon known as interferon beta-1b.
	www.mult-sclerosis.org /Betaseron.html (510 words)

	PRESS RELEASE Room-Temperature Betaseron Available Nationwide (Site not responding. Last check: 2007-11-06)
		Betaseron®, the first therapy approved in the United States to treat relapsing-remitting multiple sclerosis (MS), is the first and only room-temperature (25°C/77°F) MS therapy approved for relapsing-remitting MS.
		Delbert Richardson, who's been treated with Betaseron since he was diagnosed with MS in 1997, went on an eight-month cross-country cycling trip last year to raise awareness of the disease.
		Betaseron is the first and only therapy available as a room-temperature formulation (25°C/77°F) for relapsing-remitting MS, providing a convenient option for MS patients in the United States.
	www.marketwire.com /mw/release_html_b1?release_id=42088 (856 words)

	Betaseron Information from Drugs.com
		Betaseron is a specific interferon used in the treatment of relapse-remitting multiple sclerosis to slow the development of physical disability and to decrease the frequency of exacerbations.
		Betaseron is in the FDA pregnancy category C. This means that it is not known whether Betaseron will be harmful to an unborn baby.
		Betaseron is used as a subcutaneous (under the skin) injection.
	www.drugs.com /betaseron.html (1078 words)

	16-Year follow-up study reinforces Betaseron long-term efficacy, safety and tolerability in MS
		The median treatment duration with Betaseron of the analyzed trial participants was almost 10 years, while the longest duration on therapy is 17.1 years.
		Patients were randomly assigned to one of three study arms, Betaseron® 50 mcg, Betaseron 250 mcg or placebo, with a median duration of observation of 45 months.
		Betaseron® is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.
	www.eurekalert.org /pub_releases/2006-04/opr-1fs040406.php (804 words)

	Berlex, Inc. :: Berlex Updates Preliminary Data from the Betaseron(R) 16-Year Long-Term Follow-up Study in Patients ... (Site not responding. Last check: 2007-11-06)
		Sixteen Years of Betaseron Trials in Patients with MS The Betaseron pivotal trial was the first large, randomized, placebo- controlled study of any therapy in MS.
		Betaseron was the first therapy approved in the United States to treat relapsing-remitting MS, the most common form of the disease.
		Betaseron is the first and only interferon beta therapy available in the United States that is stable at room temperature (25 degrees C/77 degrees F) for more than 30 days, providing a convenient option for MS patients.
	sev.prnewswire.com /medical-pharmaceuticals/20050927/NYTU10527092005-1.html (1224 words)

	Betaseron(R) Pre-Filled Diluent Syringe Now Available
		It will make it easier for me to manage my disease." Betaseron is the first and only FDA-approved interferon therapy that is stable at room temperature for more than 30 days(i), and the only interferon for the treatment of relapsing forms of MS in a non-acidic formulation.
		Betaseron is indicated for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations.
		Betaseron is the first and only interferon therapy available in the United States that is stable at room temperature (25 degrees C/77 degrees F) for more than 30 days, providing a convenient option for MS patients.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-27-2004/0002096753&EDATE= (940 words)

	Betaseron Reduces Rate of MS Lesions, Though Not Duration - CME Teaching Brief® - MedPage Today
		BETHESDA, Md., Sept. 13-Although treatment with Betaseron (interferon β-1b) appears to reduce the frequency of so-called fl hole lesions, as seen by MRI scans of patients with multiple sclerosis, the drug does not contain the damage if one forms.
		Advise patients that in this very small study, Betaseron appeared to be effective at protecting the brain against some but not all new MS lesions.
		Although Betaseron has been shown to reduce formation of both fl holes and contrast-enhanced MS lesions on MRI, it had been unclear whether the drug had any effect on the duration of lesions once they've formed, wrote Dr. Bagnato and colleagues.
	www.medpagetoday.com /Neurology/MultipleSclerosis/tb/1727 (798 words)

	Preliminary Results of Betaseron(R) Sixteen-Year Long-Term Follow-up Study Suggest Positive Long-Term Impact of Early ...
		Seventy-three of the 78 identified patients (94 percent) originally assigned to the Betaseron 250 mcg group are still alive, compared with 64 of the 78 identified patients (82 percent) originally assigned to the placebo group.
		ABOUT BETASERON Betaseron was the first therapy approved in the United States to treat relapsing-remitting MS, the most common form of the disease.
		Betaseron is the first and only interferon beta therapy available in the United States that is stable at room temperature (250C/770F) for more than 30 days, providing a convenient option for MS patients.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-14-2005/0003393620&EDATE= (1459 words)

	U.S. Secondary-Progressive MS Betaseron Study Stopped Early
		Patients who elect to switch from the double-blind study to active treatment with Betaseron will continue to be medically monitored by their clinical investigators.
		Betaseron was the first therapy approved for the treatment of relapsing-remitting multiple sclerosis.
		Betaseron is already approved for secondary-progressive MS in Europe, Canada and Australia.
	www.docguide.com /dg.nsf/c199ac7acbf21b1b852565f30052a091/68100e03da63fa26852567ec0061fb5b?OpenDocument (471 words)

	Betaseron
		Betaseron is a type of protein called interferon.
		Betaseron was the first drug shown effective in the treatment of relapsing-remitting MS, setting the standard for MS therapy.
		In a two-year, double blind study for Betaseron, neither the 372 patients nor their physicians knew who was receiving Betaseron or no treatment at all.Three groups of patients received subcutaneous injections (under the skin) every other day.
	www.msakc.org /Articles/Betaseron.htm (729 words)

	News: /C O R R E C T I O N -- Berlex, Inc./. Genetic Engineering News - Biotechnology from Bench to Business
		Betaseron is the only available refrigeration-free MS therapy that can be stored at room temperature for longer than 30 days(1).
		Research has shown that Betaseron patients who participated in the B.E.T.A. Nurse program were more likely to maintain their course of therapy with nearly 90 percent of people in the program remaining on treatment after one year.
		Treatment with Betaseron has been shown to sustain reduction in the annual rate of relapses of up to 40 percent over 16 years.
	www.genengnews.com /news/bnitem.aspx?name=3274829 (1081 words)

	Betaseron - Talk Medical
		· Betaseron is a specific interferon used in the treatment of relapse-remitting multiple sclerosis to slow the development of physical disability and to decrease the frequency of exacerbations.
		You may not be able to use Betaseron, or you may require a dosage adjustment or special monitoring during treatment.
		Continue to use Betaseron and notify your doctor if you experience ·fever or chills; ·headache; ·muscle aches; ·nausea, vomiting, or loss of appetite; or ·dizziness or drowsiness.
	www.talkmedical.com /medications/785/Betaseron (677 words)

	Articles
		Betaseron, officially known as Interferon Beta -1b, is a common drug treatment for patients with relapsing-remitting Multiple Sclerosis.
		Betaseron is a type of interferon, a protein which is naturally produced by the body to function in anti-viral and immunoregulatory activities.
		Although it is still unclear as to how Betaseron works in decreasing the frequency and severity of exacerbations, it is known that it operates in conjunction with cell receptors on the surface of human cells to regulate immune responses including the body's immune response against myelin.
	www.wesleyan.edu /synthesis/GROUP1/FINAL/Betaseron.html (376 words)

	Early Treatment With Betaseron Significantly Delayed the Time to a Second Clinical Ev - BrainTalk Communities
		The new indication is based on results from the BENEFIT (BEtaseron in Newly Emerging multiple sclerosis for Initial Treatment) Study of patients with a first clinical demyelinating event and MRI features suggestive of MS.
		In the randomized, double-blind, placebo-controlled, multicenter trial, 468 participants were given either Betaseron 250 micrograms (mcg) subcutaneously every other day or placebo until they experienced a second clinical event or relapse, which confirms the diagnosis, or they had been followed for at least 24 months.
		In the study, Betaseron cut the risk of progression to the second clinical event by nearly 50 percent compared to placebo," said Mark S. Freedman, M.D., Professor of Neurology at the University of Ottawa, Ontario, Canada, and a lead investigator of the BENEFIT Study.
	brain.hastypastry.net /forums/showthread.php?t=2346 (723 words)

	Betaseron Administered in a Needle-Free System for Multiple Sclerosis (Site not responding. Last check: 2007-11-06)
		The Betaseron Needle-Free System(TM) uses a burst of carbon dioxide to propel a stream of medicine through the skin without a needle.
		Berlex is in the process of submitting an application to the FDA for the device, and expects review to be completed in less than one year.
		The Betaseron Needle-Free System(TM) will be offered through MS Centers, disease management programs with health care providers, and directly to patients through Berlex's Multiple Sclerosis Pathways patient education program.
	www.pslgroup.com /dg/9b1a.htm (567 words)

	Schering Group - Betaseron approved in the U.S. for earliest stages of Multiple Sclerosis (Site not responding. Last check: 2007-11-06)
		Betaseron is the only high-dose, high-frequency interferon beta indicated for patients at the earliest stage of MS.
		In the randomized, double-blind, placebo-controlled, multicenter trial, 468 participants were given either Betaseron 250 micrograms (mcg) subcutaneously every other day or placebo until they experienced a second clinical event which confirms the diagnosis, or they had been followed for at least 24 months.
		Treatment with Betaseron reduced the risk of progression to clinically definite MS by about 50 percent and to MRI-defined MS by 46 percent compared to placebo (2).
	schering.de /scripts/en/50_media/2006/pi/Q4/061023_earlyuse.php?... (1041 words)

	Preliminary data update from Betaseron 16 yr. long-term follow-up study in patients with MS
		95 percent of the patients originally assigned to the Betaseron 250 mcg group who have been identified are still alive, as compared with 83 percent identified as originally assigned to the placebo group.
		Sixteen Years of Betaseron Trials in Patients with MS The Betaseron pivotal trial was the first large, randomized, placebo-controlled study of any therapy in MS.
		Betaseron is the first and only interferon beta therapy available in the United States that is stable at room temperature (25°C/77°F) for more than 30 days, providing a convenient option for MS patients.
	www.eurekalert.org /pub_releases/2005-09/opr-pdu092705.php (1182 words)

	Biospace.com
		Betaseron has more than 17 years of clinical experience, with a well-established safety profile resulting from more than 700,000 patient years of treatment.
		Results of the study show that long-term continuous(6) use of Betaseron provided 13 years of cane-free mobility, which is, on average, six years longer than when compared to untreated patients from a natural history cohort.
		The study also showed that patients who continuously used Betaseron experienced a significant delay in progression to secondary progressive multiple sclerosis (SPMS) by 6.6 years compared to patients who were not on continuous Betaseron treatment.
	www.biospace.com /news_story.aspx?StoryID=34106&full=1 (1294 words)

	[No title]
		Avonex is injected into the muscle once a week at a dose of 30 mcg, whereas Betaseron is injected under the skin every other day at a dose of 250 mcg.
		Patients who are treated with Betaseron will increase their dose over several weeks according to the study protocol.
		Betaseron is the first and only interferon therapy available as a room-temperature formulation (25 degrees C/77 Degrees F) for MS, providing a convenient option for MS patients in the United States.
	www.mult-sclerosis.org /news/Mar2003/ABOVEStudyAvonexvsBetaseron.html (1167 words)

	Betaseron Changes (Site not responding. Last check: 2007-11-06)
		Berlex, Inc. reminded healthcare professionals of the prescribing information for Betaseron (interferon beta-1b) as it pertains to hepatic toxicity.
		Betaseron is approved for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.
		Liver function testing is recommended at regular intervals (one, three, and six months) following introduction to Betaseron therapy, and then periodically thereafter in the absence of clinical symptoms.
	www.mmorris.com /ms/may2005/betaseron.htm (91 words)

	PRESS RELEASE Berlex Opens Flagship ‘B.E.T.A. Center’ For MS Patients (Site not responding. Last check: 2007-11-06)
		It is the only Center of its kind dedicated to the needs of people who are on Betaseron therapy, and demonstrates the innovative, cooperative spirit that is a hallmark of Berlex.
		Betaseron was the first therapy approved in the U.S. to treat relapsing-remitting MS.
		The B.E.T.A. Center’s dedicated nurses, whose sole focus is to manage and care for Betaseron patients, provide comprehensive training for those new to treatment and those who seek a face-to-face support network of caregivers and fellow patients.
	www.marketwire.com /mw/release_html_b1?release_id=42272 (1163 words)

	MS and Betaseron
		Hello- the way the we determine who goes on disease modifying medications like Betaseron is the clinical history; how many attacks she has had in the last year and what type of MS she has, the MRI;is it active, the exam; the level of ability and other tests such as the CSF exam.
		Betaseron has been shown, as has Avonex and Copaxone, to decrease the annual relapse rates and MRI lesions on the brain.
		Betaseron is an every other day injection with flu like side effects and red spots at the site of injection so the Avonex may be more helpful in that it is only once a week and does not have the skin reactions that Betaseron has.
	www.medhelp.org /forums/neuro/archive/3720.html (350 words)

	Preliminary data update from Betaseron 16 yr. long-term follow-up study in patients with MS
		Review of the patient data from the study is ongoing and the final results are expected to be announced during 2006.
		MS is a chronic condition that requires long-term treatment, so it is important that patients and physicians have long-term information available to them to help them feel confident in their choice of treatment,“ said Ralph Makar, Vice President and General Manager, Therapeutics Business Unit, Berlex Laboratories.
		Betaseron should be used with caution in patients with depression.
	www.pharma-lexicon.com /medicalnews.php?newsid=31226 (1209 words)

	MS Neighborhood : Betaseron Scrutinized in Long-Term Study
		The results of a Betaseron pivotal trial in the late 1980s led to the approval of the drug in 1993 for the treatment of relapsing-remitting multiple sclerosis.
		This is the most common form of the disease characterized by episodes of acute worsening of symptoms followed by partial or complete recovery periods free of MS progression.
		Analysis after two years showed that significantly more patients receiving Betaseron were relapse-free, that the relapses that did occur were less severe, and that hospitalizations for MS were cut nearly in half.
	www.msneighborhood.com /content/in_the_news/archive_2235.aspx (693 words)

	Betaseron News
		Betaseron News continually updated from thousands of sources around the net.
		The USFDA has recently approved the expanded indication of Betaseron to include patients with multiple sclerosis who have experienced a first clinical episode and have MRI features consistent with MS.
		This Is MS Tysabri has retaken its place alongside Novantrone, Copaxone, Avonex, Betaseron and Rebif as the approved therapies for multiple sclerosis disease modification.
	www.topix.net /drug/betaseron (797 words)

	National MS Society \| Sourcebook: Interferons (Site not responding. Last check: 2007-11-06)
		In 2006, the FDA again extended the approval of Betaseron® to include patients with multiple sclerosis who have experienced a first clinical episode and have MRI findings that are consistent with MS.
		The new indication was based on data from the BENEFIT study, which demonstrated that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo.
		As a result, the FDA indicates that Betaseron® should be used with caution in patients with depression, and anyone experiencing symptoms of depression should report them promptly to his or her physician.
	www.nationalmssociety.org /Sourcebook-Interferons.asp (1831 words)

	Multiplesclerosis.com - FDA Approves Betaseron® for Use After the First Event Suggestive of Multiple Sclerosis
		In addition to establishing efficacy in this group of patients, the study also showed that patients with early MS found Betaseron to be a safe and well-tolerated treatment, as evidenced by the findings that 93 percent of patients completed the study.
		Treatment with Betaseron reduced the risk of progression to clinically definite MS by about 50 percent and to MRI-defined MS by 46 percent compared to placebo.
		Treatment with Betaseron delayed the time to a second clinical event by one year compared to patients in the placebo arm.
	www.multiplesclerosis.com /admin/templates/?a=337&z=50 (1360 words)

Try your search on: Qwika (all wikis)